Global Veterinary Oncology Market

Veterinary Oncology Market Size, Share, Growth Analysis, By Therapy Type (Chemotherapy, Radiation Therapy), By Animal Type (Companion Animals, Livestock Animals), By Cancer Type, By End-User, By Region - Industry Forecast 2025-2032


Report ID: SQMIG35A2515 | Region: Global | Published Date: December, 2024
Pages: 219 | Tables: 92 | Figures: 76

Veterinary Oncology Market Insights

Veterinary Oncology Market size was valued at USD 259.4 Billion in 2023 and is poised to grow from USD 290.79 Billion in 2024 to USD 725.14 Billion by 2032, growing at a CAGR of 12.10% during the forecast period (2025-2032).

The primary factors driving the market are the increased prevalence of cancer in the animal population and the rising use of veterinarian cancer therapy as a form of treatment. Growing owner desire to spend on animal healthcare and government initiatives for veterinary cancer therapy are the two main market-driving factors. Growing animal healthcare spending is occurring in developed economies. Additionally, the American Veterinary Medical Association (AVMA) predicted that 1 in 4 dogs would experience neoplasia at some point in their lifetimes.

According to the American Animal Hospital Association (AAHA), neoplastic disease was the primary cause of death in 73 out of 82 dogs and the leading cause of mortality in dogs under 1 year old. Traumatic damage is frequently caused by the condition. The feline population that has been identified to carry the feline leukemia virus (FeLV) has also been reported to be one of the main sources of lymphoma in felines. Therefore, better veterinary oncology treatment for these animals is required due to the increase in cancer incidence. The COVID-19 virus is expected to alter how people interact with their pet animals.

The majority of pet owners grew closer to their animals during the nationwide lockdowns intended to stop the spread of disease. Pet owners are encouraged to prioritize pet-friendly holidays and workplaces as life returns to normal and incorporate their pets even more into their everyday routines. Spending time with their pets improved wellbeing and helped reduce stress, according to 75% of pet owners polled by the American Pet Product Association. Adoption rates in animal shelters in the U.S. increased by as much as 40% from the previous year. Market expansion is anticipated to be supported by the trend towards pet humanization.

The market is also expanding as a result of the rising number of veterinary clinical studies being conducted to assess the efficacy and safety of various oncologic treatments for pets. To aid researchers conducting prospective veterinary clinical studies, the AVMA developed a database called the AVMA Animal Health Research Database (AAHSD). The market is expected to increase throughout the forecast period as a result of such studies by researchers who are interested in veterinary oncology treatments.

The industry is also being driven by favorable government initiatives related to the treatment of veterinary cancer. For instance, the NCI (National Cancer Institute) funded the testing of veterinary oncology medicines in animals as part of a clinical trial in July 2019. Finding novel cancer treatments that will maintain the dog's quality of life was the goal of the trials made available by veterinarian medical schools around the world. As humans and dogs share a similar biology for cancer, the experiment was also done to shed light on how the veterinary oncology therapies and techniques being tested in dogs may be applied to assist people with cancer.

US Veterinary Oncology Market is poised to grow at a sustainable CAGR for the next forecast year.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Veterinary Oncology Market size was valued at USD 259.4 Billion in 2023 and is poised to grow from USD 290.79 Billion in 2024 to USD 725.14 Billion by 2032, growing at a CAGR of 12.10% during the forecast period (2025-2032).

The market for veterinary oncology is seeing intense competition as a result of the availability of oncology treatments for veterinary use from numerous large pharmaceutical and medical device businesses. To expand their revenue share and establish their presence, market participants are concentrating on putting new tactics into practice, such as regional growth, mergers, acquisitions, the introduction of new products, collaborations, and distribution agreements. Following Elanco's acquisition of Aratana Therapeutics in, the corporation announced the creation of a commercial team focused on the veterinary specialty market. 'Zoetis Inc. (USA) ', 'Elanco Animal Health (USA) ', 'Boehringer Ingelheim (Germany) ', 'Merck Animal Health (USA) ', 'Virbac (France) ', 'Ceva Sante Animale (France) ', 'Vetoquinol (France) ', 'Dechra Pharmaceuticals (UK) ', 'IDEXX Laboratories (USA) ', 'Heska Corporation (USA) ', 'Aratana Therapeutics (USA) ', 'Karyopharm Therapeutics (USA) ', 'Regeneus Ltd. (Australia) ', 'PetCure Oncology (USA) ', 'Accuray Incorporated (USA) ', 'Varian Medical Systems (USA) ', 'Morphogenesis, Inc. (USA) ', 'Nippon Zenyaku Kogyo Co., Ltd. (Japan) ', 'Eli Lilly and Company (USA) ', 'Bayer AG (Germany) '

The rising prevalence of cancer in companion animals, such as dogs and cats, is a major driver of the veterinary oncology market. Pets are living longer, and like humans, they are susceptible to developing cancer as they age. This drives the demand for effective oncology treatments.

Increasing Focus on Personalized Medicine: Similar to human oncology, there is a growing trend in veterinary oncology towards personalized medicine. This approach involves tailoring treatment plans based on the specific characteristics of an individual animal's cancer, such as genetic mutations or biomarkers. Personalized medicine aims to improve treatment outcomes and minimize adverse effects.

North America held charge of the majority of the veterinary oncologist market in 2022, accounting for a 45.0% revenue share. The category is estimated to dominate the market for the anticipated period of time. Three major aspects that contribute to the market expansion are the increasing emphasis on pet health, the presence of several pet medicine manufacturing companies, and the rapid adoption of novel pet care treatments. Along with increased government funding for pet cancer treatments in this region, the market is also being driven by the presence of industry titans in the oncology sector.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Veterinary Oncology Market

Report ID: SQMIG35A2515

$5,300
BUY NOW GET FREE SAMPLE